Eli Lilly’s retatrutide kept stacking up obesity wins with topline Phase 3 data that show weight loss across doses in the company’s Triumph-1 program, reported ahead of further data presentations. In the trial, patients assigned to retatrutide achieved up to 28% mean body-weight reduction over 80 weeks, with gastrointestinal adverse events remaining the main side effect category. Separate coverage of the retatrutide package highlights that Lilly is positioning the triple hormone receptor agonist (GIP/GLP-1/glucagon targets) as a potentially broad, high-efficacy option as obesity competitors prepare their next registrational pushes. Additional safety signals and tolerability details are expected as Lilly prepares more complete datasets for upcoming scientific meetings and future regulatory steps.